| 摘要 |
595829 Disclosed are 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives as represented by the general formula C, wherein ring Y is (C4-C7)cycloalkyl group, and wherein the other substituents are as defined herein, with the proviso that 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3 (2H)-one and its pharmaceutically acceptable salts are excluded. Representative compounds include 1-{ 4-[3-(1-methyl-1H-imidazol-4-yl)-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl]phenyl} cyclobutanamine dihydrochloride, tert-butyl { 1-[4-(9-phenyl(1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]cyclobutyl} carbamate, 1-[4-(9-phenyl-3-pyrimidin-2-yl[1,2,4 ]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]cyclobutanamine, 1-[4-(3-methyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-5-yl)phenyl]cyclobutanamine and 1-[4-(3-cyclopropyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-5-yl)phenyl]cyclobutanamine. Also disclosed is a pharmaceutical composition which comprises a pharmaceutical carrier, and a therapeutically effective amount of a compound as defined above, useful in the treatment or prevention of cancer.
|
